Neumora Therapeutics, Inc. (NMRA) Stock Analysis

Neumora Therapeutics, Inc. (NMRA) is a publicly traded company in the HEALTHCARE sector. It trades at $1.75, carries a market capitalization of $337.22M. This page summarizes the public market data, fundamentals, and frequently asked questions for NMRA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.75
• Market Cap: $337.22M
• EPS: $-1.33
• 52-Week High: $3.65
• 52-Week Low: $0.72

Market Sentiment

Neumora Therapeutics, Inc. currently has a Neutral sentiment score of 0.11.

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to the development of transformative therapies for neuropsychiatric and neurodegenerative disorders. The company is focused on addressing significant unmet medical needs by leveraging cutting-edge science and technology to innovate treatment strategies targeted at critical biological pathways associated with complex brain diseases. With a robust pipeline of novel compounds, Ne...

GNG Research Analysis

GNG Research scores Neumora Therapeutics, Inc. (NMRA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NMRA.

Frequently Asked Questions

Does NMRA pay dividends?

Neumora Therapeutics, Inc. (NMRA) does not currently pay a regular dividend.

What is NMRA's market cap?

Neumora Therapeutics, Inc. (NMRA) has a market capitalization of $337.22M with a current stock price of $1.75.